Literature DB >> 8040300

Studies of thrombin-induced proteoglycan release in the degradation of human and bovine cartilage.

E Furmaniak-Kazmierczak1, T D Cooke, R Manuel, A Scudamore, H Hoogendorn, A R Giles, M Nesheim.   

Abstract

Because fibrin is commonly observed within arthritic joints, studies were undertaken to determine whether purified coagulation and fibrinolytic proteases degrade cartilage in vitro and to seek evidence for the activation of coagulation in arthritic joints through measurements of the levels of inhibitor-enzyme complexes and several other proteins associated with coagulation and fibrinolysis. The concentrations of 13 plasma proteins and complexes of thrombin and Factor Xa with antithrombin III were measured in synovial fluids recovered at the time of knee replacement surgery. All zymogens necessary to constitute the coagulation cascade were present. Thrombin and the combination of prothrombin plus prothrombinase induced proteoglycan release from both normal and arthritic cartilages. Factor Xa and plasmin induced release from diseased cartilage only, and urokinase, tissue plasminogen activator, and activated protein C were without effect at the levels used. At saturating levels of thrombin (> or = 2.0 microM) 80% of the proteoglycan content of normal cartilage was released within 24 h. Thrombin, which is cationic, reversibly binds cartilage with Kd = 7.0 +/- 1.0 microM and Bmax = 820 +/- 70 ng/mg of human cartilage. Levels of thrombin-antithrombin III complexes in synovial fluids and arthritis were 4-fold higher in osteo (OA) and 43-fold higher in rheumatoid (RA) than in controls (0.98 nM). Factor Xa-antithrombin III complex levels were threefold lower in OA and fivefold higher in RA than in controls (0.24 nM). These elevated levels of enzyme-inhibitor complexes imply a history of activation of coagulation within the joint, especially in RA. Since thrombin degrades cartilage in vitro and had been generated in vivo, as inferred by the existence of thrombin-antithrombin III complexes, intraarticular activation of coagulation may both contribute to the pathology of arthritis and comprise a target for therapy and diagnosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8040300      PMCID: PMC295107          DOI: 10.1172/JCI117358

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  39 in total

1.  Thrombin.

Authors:  R L Lundblad; H S Kingdon; K G Mann
Journal:  Methods Enzymol       Date:  1976       Impact factor: 1.600

2.  Chemotaxis for human monocytes by fibrinogen-derived peptides.

Authors:  D L Richardson; D S Pepper; A B Kay
Journal:  Br J Haematol       Date:  1976-04       Impact factor: 6.998

3.  Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma.

Authors:  B Wiman; D Collen
Journal:  Eur J Biochem       Date:  1977-08-15

4.  A simple method for preparing fibrinogen.

Authors:  W Straughn; R H Wagner
Journal:  Thromb Diath Haemorrh       Date:  1966-07-31

Review 5.  Human plasminogen.

Authors:  F J Castellino; J R Powell
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

Review 6.  Cell-to-cell interactions in the secretion of enzymes of connective tissue breakdown, collagenase and proteoglycan-degrading neutral proteases. A review.

Authors:  G Vaes
Journal:  Agents Actions       Date:  1980-12

Review 7.  Factor V.

Authors:  M E Nesheim; J A Katzmann; P B Tracy; K G Mann
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

Review 8.  Prothrombin.

Authors:  K G Mann; J Elion; R J Butkowski; M Downing; M E Nesheim
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

9.  Phospholipid-binding properties of bovine factor V and factor Va.

Authors:  J W Bloom; M E Nesheim; K G Mann
Journal:  Biochemistry       Date:  1979-10-02       Impact factor: 3.162

10.  Activation of protein C and its distribution between its inhibitors, protein C inhibitor, alpha 1-antitrypsin and alpha 2-macroglobulin, in patients with disseminated intravascular coagulation.

Authors:  M F Scully; C H Toh; H Hoogendoorn; R P Manuel; M E Nesheim; S Solymoss; A R Giles
Journal:  Thromb Haemost       Date:  1993-05-03       Impact factor: 5.249

View more
  13 in total

Review 1.  A fibrin based model for rheumatoid synovitis.

Authors:  O Sánchez-Pernaute; R Largo; E Calvo; M A Alvarez-Soria; J Egido; G Herrero-Beaumont
Journal:  Ann Rheum Dis       Date:  2003-12       Impact factor: 19.103

2.  Innovative use of recombinant activated factor VII during physical rehabilitation in an Italian child with Glanzmann's thromboasthenia.

Authors:  Paola Giordano; Giuseppe Lassandro; Riccardina Tesse; Stefania Longo; Federica Valente; Anna Rita Cappiello; Antonio Coppola
Journal:  Blood Transfus       Date:  2012-07-04       Impact factor: 3.443

Review 3.  Thrombomodulin and its role in inflammation.

Authors:  Edward M Conway
Journal:  Semin Immunopathol       Date:  2011-07-31       Impact factor: 9.623

4.  Effect of thrombin inhibition on synovial inflammation in antigen induced arthritis.

Authors:  P A Varisco; V Péclat; K van Ness; A Bischof-Delaloye; A So; N Busso
Journal:  Ann Rheum Dis       Date:  2000-10       Impact factor: 19.103

5.  Activated protein C inhibits proliferation and tumor necrosis factor α-stimulated activation of p38, c-Jun NH2-terminal kinase (JNK) and Akt in rheumatoid synovial fibroblasts.

Authors:  Sohel M Julovi; Kaitlin Shen; Kelly Mckelvey; Nikita Minhas; Lyn March; Christopher J Jackson
Journal:  Mol Med       Date:  2013-10-24       Impact factor: 6.354

6.  Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis.

Authors:  Nobuchika Yamamoto; Fumihiko Sakai; Shigeyuki Kon; Junko Morimoto; Chiemi Kimura; Harumi Yamazaki; Ikuko Okazaki; Nobuo Seki; Takashi Fujii; Toshimitsu Uede
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

7.  Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX.

Authors:  Junjiang Sun; Narine Hakobyan; Leonard A Valentino; Brian L Feldman; R Jude Samulski; Paul E Monahan
Journal:  Blood       Date:  2008-08-20       Impact factor: 22.113

8.  Thrombin-activatable carboxypeptidase B cleavage of osteopontin regulates neutrophil survival and synoviocyte binding in rheumatoid arthritis.

Authors:  Shadi A Sharif; Xiaoyan Du; Timothy Myles; Jason J Song; Elizabeth Price; David M Lee; Stuart B Goodman; Mariko Nagashima; John Morser; William H Robinson; Lawrence L K Leung
Journal:  Arthritis Rheum       Date:  2009-10

Review 9.  Intradiscal platelet-rich plasma (PRP) injections for discogenic low back pain: an update.

Authors:  Michael Monfett; Julian Harrison; Kwadwo Boachie-Adjei; Gregory Lutz
Journal:  Int Orthop       Date:  2016-04-12       Impact factor: 3.075

Review 10.  Serpins in cartilage and osteoarthritis: what do we know?

Authors:  David J Wilkinson
Journal:  Biochem Soc Trans       Date:  2021-04-30       Impact factor: 5.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.